Filing Flows › Foghorn Therapeutics (FHTX) › Q3 2026 › vs Q3 2025
Foghorn Therapeutics (FHTX) Q3 2026 vs Q3 2025 (year over year)
Foghorn Therapeutics's revenue rose $75.4M (+925%) from $8.2M in Q3 2025 to $83.5M in Q3 2026. Operating margin 67.8% against -226.9% (+294.7 pts).
Foghorn Therapeutics, Q3 2026: revenue $83.5M (+925% year over year), operating margin 67.8%, net earnings $58.1M, operating cash flow −$18.2M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 67.8% | -226.9% | +294.7 pts |
| Net margin | 69.6% | -194.4% | +264.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $83.5M | $8.2M | $75.4M | +925% |
| Other income, net | $1.5M | $2.7M | −$1.1M | -43% |
| Operating profit | $56.6M | −$18.5M | $75.1M | — |
| Costs & expenses | $26.9M | $26.7M | $250K | +0.9% |
| Pre-tax earnings | $58.1M | −$15.8M | $74.0M | — |
| Research & development | $18.8M | $20.0M | −$1.2M | -6% |
| General & admin | $5.8M | $6.7M | −$856K | -13% |
| Net earnings | $58.1M | −$15.8M | $74.0M | — |
| Operating cash sources | $79.1M | $6.6M | $72.5M | 12× |
| Depreciation & amortization | $200K | $900K | −$700K | -78% |
| Share-based compensation | $2.5M | $2.7M | −$213K | -8% |
| Cash used in operations | $18.2M | $18.9M | −$617K | -3% |
| Working capital & other | $79.1M | $6.6M | $72.5M | 12× |
Questions
How much did Foghorn Therapeutics's revenue grow year over year in Q3 2026?
Foghorn Therapeutics's revenue rose $75.4M (+925%) from $8.2M in Q3 2025 to $83.5M in Q3 2026. Operating margin 67.8% against -226.9% (+294.7 pts).